RECRUITING

Skeletal Health and Bone Marrow Composition in Adolescents With Cystic Fibrosis

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The investigators will be evaluating bone marrow composition via magnetic resonance imaging in adolescents diagnosed with cystic fibrosis (CF) compared to healthy, matched controls. The investigators will also be assessing their bone mineral density via other imaging modalities, including dual-energy X-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT). This longitudinal project will focus on abnormalities in bone marrow composition, and specifically whether adolescents with diagnosed with CF exhibit increased bone marrow fat, its association with bone mineral density (BMD) and the underlying pathophysiology, including glycemic control, inflammation, and bone turnover markers.

Official Title

Skeletal Health and Bone Marrow Composition in Adolescents With Cystic Fibrosis

Quick Facts

Study Start:2024-04-01
Study Completion:2029-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06216704

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:13 Years to 20 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * 13-20 years old
  2. * Cystic fibrosis with pancreatic insufficiency
  3. * Must have a stable treatment regimen, including CFTR modulator usage unchanged for the prior three months
  4. * Liver transplant recipients will be eligible, as long as they are at least 1 year post-transplant and are no longer on Prednisone for immunosuppressive therapy
  1. * Diagnosis of other chronic disease affecting bone health
  2. * Active use (within the past 3 months) of medications that are known to affect skeletal metabolism
  3. * CF exacerbation or glucocorticoid exposure within the prior 1 month
  4. * Lung transplant

Contacts and Locations

Study Contact

Rebecca Gordon, MD
CONTACT
(617) 355-7476
rebecca.gordon@childrens.harvard.edu

Principal Investigator

Rebecca Gordon, MD
PRINCIPAL_INVESTIGATOR
Boston Children's Hospital

Study Locations (Sites)

Boston Children's Hospital
Boston, Massachusetts, 02115
United States

Collaborators and Investigators

Sponsor: Boston Children's Hospital

  • Rebecca Gordon, MD, PRINCIPAL_INVESTIGATOR, Boston Children's Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-01
Study Completion Date2029-06-30

Study Record Updates

Study Start Date2024-04-01
Study Completion Date2029-06-30

Terms related to this study

Keywords Provided by Researchers

  • Cystic Fibrosis
  • Bone Marrow
  • Dual-energy X-ray absorptiometry
  • Peripheral Quantitative Computed Tomography
  • Magnetic Resonance Imaging
  • pediatrics
  • bone health

Additional Relevant MeSH Terms

  • Cystic Fibrosis